A detailed history of Orbimed Advisors LLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 435,900 shares of RYTM stock, worth $24.5 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares
435,900
Previous 704,842 38.16%
Holding current value
$24.5 Million
Previous $28.9 Million 21.09%
% of portfolio
0.54%
Previous 0.7%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$40.81 - $55.0 $11 Million - $14.8 Million
-268,942 Reduced 38.16%
435,900 $22.8 Million
Q1 2024

May 15, 2024

BUY
$39.12 - $52.44 $6.58 Million - $8.82 Million
168,200 Added 31.34%
704,842 $30.5 Million
Q4 2023

Feb 14, 2024

SELL
$21.39 - $49.64 $1.01 Million - $2.33 Million
-47,000 Reduced 8.05%
536,642 $24.7 Million
Q3 2023

Nov 14, 2023

BUY
$15.81 - $27.8 $9.23 Million - $16.2 Million
583,642 New
583,642 $13.4 Million
Q3 2019

Nov 14, 2019

SELL
$18.62 - $24.51 $14.7 Million - $19.3 Million
-787,300 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$24.76 - $31.66 $3.5 Million - $4.47 Million
-141,200 Reduced 15.21%
787,300 $21.6 Million
Q4 2018

Feb 14, 2019

SELL
$24.11 - $31.34 $2.72 Million - $3.54 Million
-112,853 Reduced 10.84%
928,500 $25 Million
Q3 2018

Nov 14, 2018

SELL
$26.99 - $35.85 $27.6 Million - $36.7 Million
-1,023,647 Reduced 49.57%
1,041,353 $30.4 Million
Q2 2018

Aug 14, 2018

SELL
$17.02 - $35.2 $14.2 Million - $29.4 Million
-836,295 Reduced 28.82%
2,065,000 $64.6 Million
Q4 2017

Feb 14, 2018

BUY
$22.0 - $30.51 $63.8 Million - $88.5 Million
2,901,295
2,901,295 $43.5 Million

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.13B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.